The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences
On October 22, 2026, Gilead Sciences, a biopharmaceutical company pursuing breakthroughs in medicine, announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company, for $1.275 billion in upfront cash consideration, subject to customary adjustments. The transaction is expected to close later in 2026. Wilson Sonsini Goodrich & Rosati is advising PepStar on patent matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Prana Therapies on IP Matters Related to Acquisition by Bolt Biotherapeutics
On October 23, 2026, Bolt Biotherapeutics, a clinical-stage biotechnology company, announced the acquisition of Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, Bolt Biotherapeutics will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned. Wilson Sonsini Goodrich & Rosati advised Prana Therapies on the intellectual property matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Otter.ai on $320 Million Growth Investment
On October 20, 2026, Otter.ai, the company behind the leading AI notetaker and conversational knowledge platform, announced $320 million in growth financing from General Catalyst's Customer Value Fund. Wilson Sonsini Goodrich & Rosati advised Otter.ai on the transaction.
Client Highlights
Wilson Sonsini Advises ElevenLabs on $300 Million Employee Tender Offer
On September 30, 2026, ElevenLabs, a voice technology research company, announced the closing of a $300 million employee tender offer that values the company at $22 billion, doubling its valuation at its Series D financing in February 2026. The tender offer was led by Wellington and T. Rowe Price, with participation from new investors BDT & MSD, EQT, GIC, Goldman Sachs, OTPP, and Sapphire Ventures, as well as existing investors including Alkeon, Andreessen Horowitz, D.E. Shaw, DISRUPTIVE, Evantic, ICONIQ, and Lightspeed. Wilson Sonsini Goodrich & Rosati advised Elevenlabs on the transaction.
Client Highlights
Wilson Sonsini Advises Tenstorrent on $1.5 Billion Series E Financing
On October 19, 2026, Tenstorrent, an artificial intelligence (AI) computing company, announced it has closed $1.5 billion in Series E funding at a $6.2 billion post-money valuation. The round was led by Trace Capital and Innovation X, with participation from new and existing investors including Agostinelli Group, ARK Invest, Brett Barna, Cadence Ventures, Eclipse, Fidelity Management & Research Company, Maverick Silicon, Morgan Stanley, Protagonist, Sandisk, T. Rowe Price, Tether Investments, Troluce Capital, Virtu Financial, and XTX Markets. Wilson Sonsini Goodrich & Rosati represented Tenstorrent on the transaction.
Client Highlights
Firm Advises Clearway on Agreements with PacifiCorp for Additional 210 MW of Battery Energy Storage in Utah
On October 9, 2026, Clearway Energy Group (Clearway) announced an additional 210 megawatts (MW) of battery energy storage to its Honeycomb Energy Center fleet in southern Utah, supported by long-term contracts with PacifiCorp. The new storage capacity will help balance supply and demand on Utah’s electrical grid. Wilson Sonsini Goodrich & Rosati advised Clearway on the transaction with PacifiCorp.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.